AI, Digitalization, and Advanced Synthesis in Pharma Manufacturing

In this episode, we speak with François Ricard, Christian Seufert, and Jan Vertommen from Lonza’s Advanced Synthesis platform about how AI-driven process innovation is shaping the development and manufacture of complex molecules.

Tune in to hear how pharmaceutical manufacturing is moving toward more data-driven approaches. From AI-based route scouting to process optimization, our guests discuss how these tools are being applied in practice to improve decision-making and reduce uncertainty in early-stage processes.

They also explore advances in conjugation and bioavailability enhancement, including how new approaches can help identify likely solid-state forms. Together, these innovations support the development and manufacture of increasingly complex, difficult-to-make molecules.


*The presented information was correct and current at the time of publication.


​​
Key Concepts in Context:

AI-driven process development focuses on specific manufacturing challenges, using targeted tools to help accelerate development and improve decision-making.

Route scouting and design optimization use AI-based models to identify efficient synthetic routes while also considering supply chain constraints from the earliest stages.

Conjugation and bioconjugation technologies support the development of complex modalities such as antibody-drug conjugates, where containment, scalability, and process efficiency are critical.

Bioavailability enhancement approaches, including co-crystal screening, help guide the identification of likely solid-state forms for small molecules.

Hybrid human-in-the-loop models combine AI outputs with scientific expertise, helping teams interpret results and apply them in process development.

Past Episodes

Season 4
Season 3
Season 2
Season 1